Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fengyinhe Holdings | Hong Kong | Financial | Investment Banking & Investment Services | 322.7% | HK$315.47M | 0.9x | -0.2 | HK$0.94 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Huarong International Financial | Hong Kong | Financial | Investment Banking & Investment Services | 257.9% | HK$1.72B | -4.7x | -0.06 | HK$0.20 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Capital VC | Hong Kong | Financial | Investment Banking & Investment Services | 115% | HK$93.18M | -1.2x | -0.05 | HK$0.21 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Holly Futures Co | Hong Kong | Financial | Investment Banking & Investment Services | 97.2% | HK$2.90B | 116.6x | 1.54 | HK$2.87 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Investment and Finance | Hong Kong | Financial | Investment Banking & Investment Services | 88.7% | HK$206.30M | -12.2x | -0.15 | HK$0.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ARTA TechFin | Hong Kong | Financial | Investment Banking & Investment Services | 78.3% | HK$784.87M | -20x | -0.32 | HK$0.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Everest Med | Hong Kong | Healthcare | Pharmaceuticals | 65.7% | HK$2.44B | -6.2x | HK$40.60 | 18.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Capital Estate | Hong Kong | Financial | Investment Banking & Investment Services | 51.9% | HK$79.68M | 14.3x | 0.12 | HK$0.44 | 8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | 47.5% | HK$2.89B | -121.8x | -1.72 | HK$4.75 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | 42.5% | HK$16.93B | -5.5x | 0.6 | HK$18.12 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
Sands China | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | 39.3% | HK$163.89B | 20.1x | 0.07 | HK$20.30 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.5% Upside | Upgrade to Pro+ | |
OSL | Hong Kong | Technology | Financial Technology (Fintech) & Infrastructure | 39.3% | HK$4.87B | -21.5x | -0.58 | HK$7.88 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -17% Downside | Upgrade to Pro+ | |
Gaoyu Finance | Hong Kong | Financial | Banking Services | 37.5% | HK$49.98M | 21x | 0.34 | HK$0.02 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | 30.2% | HK$13.37B | -34.3x | -0.56 | HK$41.95 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.5% Upside | Upgrade to Pro+ | |
China Merchants China Direct | Hong Kong | Financial | Investment Banking & Investment Services | 21.8% | HK$2.22B | 187.6x | 1.68 | HK$14.60 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tong Tong AI Social | Hong Kong | Financial | Banking Services | 17.9% | HK$1.72B | 16x | 0.04 | HK$0.34 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Melco Int Development | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | 16.4% | HK$6.33B | -6x | -0.08 | HK$5.02 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.1% Upside | Upgrade to Pro+ | |
Galaxy Entertainment Group | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | 16.3% | HK$153.85B | 18.5x | 0.01 | HK$35.10 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | 10.2% | HK$13.47B | -0.3x | -1.68 | HK$126.90 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.1% Upside | Upgrade to Pro+ | |
DT Capital | Hong Kong | Financial | Investment Holding Companies | 8.2% | HK$177.79M | -21.7x | -0.34 | HK$0.07 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Graphene | Hong Kong | Real Estate | Real Estate Operations | 6.8% | HK$495.51M | 26x | 0.49 | HK$0.08 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dynamic | Hong Kong | Real Estate | Real Estate Operations | 5.1% | HK$1.78B | 0.3x | 0 | HK$7.51 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sunwah Kingsway Capital | Hong Kong | Financial | Investment Banking & Investment Services | 0.5% | HK$164.54M | -2.9x | -0.1 | HK$0.22 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orient Securities Int | Hong Kong | Financial | Banking Services | 0% | HK$19.49M | 6.9x | 0.02 | HK$0.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zhaoke Ophthalmology | Hong Kong | Healthcare | Pharmaceuticals | -3.6% | HK$737.29M | -3.1x | -0.06 | HK$1.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MGM China Holdings | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -3.8% | HK$37.47B | 8.4x | 0.03 | HK$9.85 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pinestone Capital | Hong Kong | Financial | Investment Banking & Investment Services | -4.8% | HK$58.74M | -4.8x | -0.06 | HK$0.22 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | -5.7% | HK$229.19M | -0.4x | -0.13 | HK$2.69 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | -7% | HK$1.36B | -5.9x | 0.92 | HK$0.32 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CL | Hong Kong | Financial | Investment Banking & Investment Services | -11.4% | HK$81.40M | 3.4x | 0.02 | HK$0.03 | -12.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |